熱門資訊> 正文
Pliant结束特发性肺纤维化资产bexotegrast的开发
2025-06-28 04:32
- Pliant Therapeutics is ending development of idiopathic pulmonary fibrosis candidate bexotegrast following poor phase 2b/3 results.
- In March, the company ended the BEACON-IPF trial following a Data Safety Monitoring Board recommendation. Analysis of data found that bexotegrast-treated participants had an increased risk of experiencing adverse events associated with IPF disease progression
- In May, Pliant cut ~45% of its workforce.
- The pharma said it will continue development of PLN-101095, an oral candidate in a phase 1 open-label trial as monotherapy and in combination with Keytruda (pembrolizumab) in solid tumors resistant to immune checkpoint inhibitors.
- Pliant is up ~13% in after-hours trading Friday.
More on Pliant Therapeutics
- Pliant Therapeutics: An Activist On Deck
- Pliant Therapeutics to trim about 45% of workforce
- Seeking Alpha’s Quant Rating on Pliant Therapeutics
- Historical earnings data for Pliant Therapeutics
- Financial information for Pliant Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
